Trial Profile
To Assess Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Among Morbidly Obese Patients With Non-Valvular Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association